

# Teaser Memorandum

MYCOPLUS CO. LTD.

**Title(Name of Technology) :**

**Natural compound, MP101, for control of dandruff and seborrheic dermatitis**

November 28, 2012

## Executive Summary

- 2000. 07. 06

- Approximately 10 natural bioactive compounds are either being developed in the lab or are on the way of being patented. They are involved in antibiotics-resistant pathogens, oral and respiratory diseases, acne, inflammatory skin, dandruff, seborrheic dermatitis, atopic dermatitis, psoriasis, tineas, candidiasis and so on.

- Mycoplus was established with the goals of developing natural medicinal candidates, healthy food ingredients and cosmeceutical products.

- Treatment of dandruff and seborrheic dermatitis

- natural compound with superiority at its efficacy

### Industry Sector:

medicine and cosmetics

### Therapeutic Target:

dandruff and seborrhea-causing pathogen

**State of Development:** registered as cosmetics ingredient

## Key Technology Highlights

☐ Natural compound with approx. m.w 290, derived from a fungal liquid fermentation.

☐ Shows strong efficacy against *Pytropsorium ovale* at 0.02 ug/ml

☐ No cytotoxicity observed

## Proposal Abstract

## ■ IP Owner Summary

MYCOPLUS Co., Ltd.

## ■ Personal Description of Researcher

☐ Name: Cheol-Sik Yoon

☐ Present Position: CEO

☐ Major: Microbiology

☐ Research interest.: Bioactive compound derived from fungi

☐ Office address: 201 Myung Seong Bldg., 996-2 Hogue-dong, Dongan-gu, Anyang, Gyeonggi-do, 431-080 Korea

## ■ Market Feasibility

☐ Domestic and foreign market size:

☐ Domestic and foreign market opportunity (competitors and competing product):

## ■ Trend & Partnership

☐ Future outlook and trends related to technology:

☐ Technology Transfer and Commercialization conditions: We intend to enter into a technology transfer or licensing transaction with respect to our technologies including active ingredients and related bioprocess technology.

☐ Type of business relationship sought (including licensing availability):

## Technology Overview

### ■ Technology Platform


- Natural compound with approx. m.w 290, derived from a fungal liquid fermentation.
- Shows strong efficacy against *Pytropsorium ovale* at 0.02 ug/ml
- No cytotoxicity observed
- Registered as cosmetics ingredient

### ■ Background and unmet needs

### ■ Discovery and Achievements

#### (Compound submission only)

- Treatment of dandruff and seborrheic dermatitis
- Antibiotic activity against *P. ovale*
- Strong efficacy against *P. ovale*
- MIC : 0.02 ug/ml
- Shampoo, hair tonic, skin and serum contained MP101 were examined on seborrheic patients who suffered from dandruff and seborrheic dermatitis(inflammation) on the scalp and face for one month. It was found that the products improved the symptom by 34.3% and 73% after one and half and one month treatments, respectively.



■ Toxicological data

	Cell toxicity	Skin Allergy	Photo toxicity	Skin toxicity (Rat)
Results	None	None	None	None

Patents and Publications

TABLE

Country	Patent, Publication or Appln. No.	Status	Description

Contact Point

KHIDI (Korea Health Industry Development Institute) is currently receiving inquiries from interested parties in this transaction. If you are interested, please contact any of the KHIDI professionals below:

Name	Title	Tel. number	E-mail address